Advertisement
Research ArticleArticle

Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues

Heather A. Dunkerley, Douglas G. Tilley, Daniel Palmer, Hanguan Liu, Sandra L. Jimmo and Donald H. Maurice
Molecular Pharmacology May 2002, 61 (5) 1033-1040; DOI: https://doi.org/10.1124/mol.61.5.1033
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues

Heather A. Dunkerley, Douglas G. Tilley, Daniel Palmer, Hanguan Liu, Sandra L. Jimmo and Donald H. Maurice
Molecular Pharmacology May 1, 2002, 61 (5) 1033-1040; DOI: https://doi.org/10.1124/mol.61.5.1033
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement